Innovation Pharmaceuticals Inc (IPIX)

[alexwv]

CTIX Latest DD- Possible Near-Term Catalysts
"* Kevetrin Phase 1 entering 8th Cohort with no prior phase 1 limiting DLTs or MTD yet observed. Dosing now into the higher of the anticipated efficacy range. Cohort 8 215MG, 33% increase. Possible MTD by cohort 9/10
* K in combination against renal completed most if not all preclinical work.
* K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start
* K against Retinoblastoma announced in March 2013 will commence soon
* Prurisol bridge study enrollment complete. Abracavir conversion will result in phase 2/3
* B against ABSSSI now 70% enrolled and treated NO AE's.
* B Review board meeting July
* Large pharma discussions underway possible announcement after July review board meeting. Possible BTD on B after review meeting or by end of trial if results match or beat Daptomycyn
* B OM completed final formulation work and expected to submit INDA to FDA.
* B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
* B otic also in formulation studies at Dr Reddy's
* B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
*B NY/ NJ universities material transfer agreement defensive mimetics
*Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution.

Thanks BK! Anyone have anything else to add?